" class="no-js "lang="en-US"> Amphista Therapeutics Archives - Medtech Alert
Monday, April 15, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Amphista Therapeutics Appoints Dr Martin Pass as CDO

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the […]

Amphista Therapeutics Appoints CBO, Beverley Carr

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the […]

Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the […]

Amphista Therapeutics Expands Research Team by Appointing Martin O'Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry

Amphista Therapeutics, a Targeted Protein Degradation (TPD) biopharmaceutical company creating first-in-class cancer therapeutics that harness […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more